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Although organic nitrates have been clinically used for
more than a century, findings in the last decade have rad-
ically challenged our traditional view concerning the
mechanism(s) of their clinical effects. This presentation
will make four separate points.
1. There is no doubt that when given acutely, they
relieve cardiac ischemia and can reduce pulmonary
congestion. Unfortunately when given chronically,
without nitrate – free intervals, these beneficial effects
are lost.
2. There is now strong evidence that chronic therapy is
associated with increased bioavailability of reactive
oxygen species and that this phenomenon may result
in both tolerance and adverse effects on endothelial
function.
3. There continues to be no evidence that these widely
used drugs improve long-term outcome in patients
with angina or congestive heart failure (except when
given in combination with hydralazine in patients
with congestive heart failure).
4. Paradoxically there is now clear evidence that short-
term administration of nitroglycerin and other organic
nitrates are potent pharmacologic preconditioning
agents and that short-term exposure (generally 2
hours) protects from the impact of ischemia reper-
fusion injury up to 48 hours later. We will also discuss
the mechanism of this preconditioning effect.
While their hemodynamic properties are well known, the
knowledge that nitrates possess previously unexpected
nonhemodynamic effects is a unique opportunity of
which clinicians should be aware. Our group believes that
tolerance, increased free radical bioavailability and their
ability to precondition are likely all interrelated. A PDF of
a recent editorial from our group is attached.
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